Orion Oyj (OTCMKTS:ORINY - Get Free Report) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $31.32 and last traded at $31.32, with a volume of 250 shares. The stock had previously closed at $30.63.
Wall Street Analysts Forecast Growth
Separately, Nordea Equity Research downgraded Orion Oyj to a "hold" rating in a research report on Tuesday, February 4th.
Check Out Our Latest Report on ORINY
Orion Oyj Stock Down 0.9 %
The business's 50 day simple moving average is $29.25 and its 200 day simple moving average is $26.05. The company has a current ratio of 2.42, a quick ratio of 1.41 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $8.95 billion, a PE ratio of 25.16 and a beta of 0.15.
Orion Oyj (OTCMKTS:ORINY - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The company reported $0.23 EPS for the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%. The company had revenue of $373.03 million during the quarter. On average, equities research analysts forecast that Orion Oyj will post 1.18 earnings per share for the current year.
Orion Oyj Increases Dividend
The business also recently announced a dividend, which was paid on Tuesday, April 29th. Stockholders of record on Monday, April 7th were given a dividend of $0.4478 per share. The ex-dividend date was Monday, April 7th. This is an increase from Orion Oyj's previous dividend of $0.24. Orion Oyj's payout ratio is currently 24.43%.
Orion Oyj Company Profile
(
Get Free Report)
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.
Featured Articles
Before you consider Orion Oyj, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orion Oyj wasn't on the list.
While Orion Oyj currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
